FA
LEGN icon

Forefront Analytics’s Legend Biotech LEGN Stock Holding History

Forefront Analytics’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$283K Buy
+15,659
New +$299K 0.26% 28
2025
Q2 		– Sell
-6,429
Closed -$219K – 50
2025
Q1 		$219K Buy
+6,429
New +$231K 0.25% 32

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FBIL
First Beijing Investment Ltd Hong Kong $2.32B AUM 8.06% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Forefront Analytics's LEGN Position: Q1 2026 in Review

Forefront Analytics opened a new position in Legend Biotech (LEGN) in Q1 2026: 15,659 shares worth $283K. The stake represents 0.26% of the portfolio and ranks #28 among its holdings. This is a return to the name: Forefront Analytics previously reported a position in LEGN as recently as Q1 2025.

Forefront Analytics first reported a position in LEGN in Q1 2025 and has held it in 2 quarters since. 189 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

  • Forefront Analytics held 15,659 shares of Legend Biotech worth $283K as of Q1 2026.
  • Legend Biotech was a new Forefront Analytics position in Q1 2026.
  • Legend Biotech made up 0.26% of Forefront Analytics's portfolio in Q1 2026, its #28 holding.
  • Forefront Analytics first reported a position in Legend Biotech in Q1 2025 and has held it in 2 quarters since.
  • 189 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on Forefront Analytics's 13F filing for Q1 2026, filed 13 May 2026.